A new era for Dynaflow Resolve
We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…
Fluicell makes in vitro development progress in type 1 diabetes therapeutics program
Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…
16
Mar
2023
Fluicell at TERMIS-EU in Manchester
We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…
14
Mar
2023
New research suggests pathway towards emergence of living cells
The cell membrane plays a crucial role for the function of biological cells. Understanding how cell-like membrane compartments…
08
Mar
2023
Fluicell publishes 2022 Q4 Year-end report
Today, February 24 2023, Fluicell publishes the Q4 Year-end report for the period January to December, 2022. The…
24
Feb
2023
Spheroid bioprinting for disease modeling
Spheroids are a powerful tool for in vitro tissue and disease modeling, with multiple applications across cancer and…
16
Feb
2023
Fluicell is growing
Do you want to be part of an innovative team pushing the boundaries in 3D bioprinting, engineered tissue-based…
30
Jan
2023
Fluicell CEO Newsletter 05, 2022
2022 has been a busy year for us at Fluicell. Not only have we this year released Biopixlar…
20
Dec
2022
Fluicell publishes report for the third quarter 2022
Today, November 30 2022, Fluicell publishes the interim report for the period July 1 to September 30, 2022….
30
Nov
2022